- Azemiglitazone
-
- $52.00 / 5mg
-
2026-04-13
- CAS:1133819-87-0
- Min. Order:
- Purity: 98.29%
- Supply Ability: 10g
|
| | 5-(4-(2-(3-METHOXYPHENYL)-2-OXOETHOXY)BENZYL)THIAZOLIDINE-2,4-DIONE Basic information |
| Product Name: | 5-(4-(2-(3-METHOXYPHENYL)-2-OXOETHOXY)BENZYL)THIAZOLIDINE-2,4-DIONE | | Synonyms: | 5-(4-(2-(3-METHOXYPHENYL)-2-OXOETHOXY)BENZYL)THIAZOLIDINE-2,4-DIONE;5-[[4-[2-(3-Methoxyphenyl)-2-oxoethoxy]phenyl]methyl]-2,4-thiazolidinedione;MSDC 0602;MSDC-0602; MSDC0602; MSDC 0602;2,4-Thiazolidinedione, 5-[[4-[2-(3-methoxyphenyl)-2-oxoethoxy]phenyl]methyl]-;Azemiglitazone;Mitochondrial Metabolism,Azemiglitazone,inhibit,MSDC-0602,Inhibitor,MSDC0602;Azemiglitazone (MSDC-0602) | | CAS: | 1133819-87-0 | | MF: | C19H17NO5S | | MW: | 371.41 | | EINECS: | | | Product Categories: | | | Mol File: | 1133819-87-0.mol |  |
| | 5-(4-(2-(3-METHOXYPHENYL)-2-OXOETHOXY)BENZYL)THIAZOLIDINE-2,4-DIONE Chemical Properties |
| Melting point | >176°C (dec.) | | storage temp. | Hygroscopic, -20°C Freezer, Under inert atmosphere | | solubility | DMSO (Slightly), Methanol (Slightly, Heated) | | form | Solid | | color | Pale Yellow to Light Yellow |
| | 5-(4-(2-(3-METHOXYPHENYL)-2-OXOETHOXY)BENZYL)THIAZOLIDINE-2,4-DIONE Usage And Synthesis |
| Uses | MSDC 0602, an analogue ofthiazolidinediones, exhibits low affinity for binding and activation of peroxisome proliferator-activated receptor γ (PPARγ). Thiazolidinediones are effective insulin-sensitizing drugs for treating various metabolic and inflammatory diseases. | | in vivo | Azemiglitazone (2-5 μM in blood, p.o for 2-4 weeks) improves insulin sensitivity in striated muscle, adipose tissue, and liver of DIO C57BL/6 mice[6].
Azemiglitazone (2-5 μM in blood, p.o for 2-4 weeks) improves mitochondrial respiratory rate in DIO C57BL/6 mice[6].
Azemiglitazone reduces NASH caused liver injury, prevents (2-5 μM in blood, p.o. for 12 weeks) and reverses (2-5 μM in blood, p.o. for 3 weeks) stellate cells activation and fibrosis in HTF-C diet feeding C57BL6/J mice[4].
Azemiglitazone (2-5 μM in blood, p.o.) causes weight loss and suppresses stellate cell activation with or without MPC function in HTF-C diet feeding LS-Mpc2-/-C57BL6/J mice[4].
| Animal Model: | HTF-C diet feeding C57BL6/J mice [4] | | Dosage: | 331 ppm MSDC-0602 potassium salt (2-5 μM Azemiglitazone in blood) | | Administration: | oral administration for 12 weeks (after 4 weeks of HTF-C diet) or 3 weeks (16 weeks after HTF-C diet) | | Result: | Induced weight loss, decreased concentrations of plasma ALT and AST and stellate cell activation. |
| Animal Model: | HTF-C diet feeding LS-Mpc2-/-C57BL6/J mice [4] | | Dosage: | 331 ppm MSDC-0602 potassium salt (2-5 μM Azemiglitazone in blood) | | Administration: | oral administration for 12 weeks (after 4 weeks of HTF-C diet) | | Result: | Induced weight loss, suppressed stellate cell activation. |
| Animal Model: | diet induced obesity C57BL/6 mice[6] | | Dosage: | 300 ppm MSDC-0602 (2-5 μM Azemiglitazone in blood) | | Administration: | oral administration for 2-4 weeks | | Result: | Reduced insulin concentration in plasma, increased glucose infusion rate and glucose uptake into gastrocnemius, adipose tissue, and heart.
Improved mitochondrial oxygen consumption. |
|
| | 5-(4-(2-(3-METHOXYPHENYL)-2-OXOETHOXY)BENZYL)THIAZOLIDINE-2,4-DIONE Preparation Products And Raw materials |
|